Acute Pancreatitis Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approval, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight
Acute Pancreatitis companies include Boston Scientific Corporation, AnGes, Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Hemostemix Inc., Caladrius Biosciences, Reven Pharmaceuticals, New Beta Innovation Limited, BioGenCell Ltd., Abbott, among several others.
(Albany, USA) DelveInsight's ' Acute Pancreatitis Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of Acute Pancreatitis, historical and forecasted epidemiology as well as the Acute Pancreatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Acute Pancreatitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Acute Pancreatitis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Acute Pancreatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Acute Pancreatitis market.
Some facts of the Acute Pancreatitis Market Report are:
The Acute Pancreatitis therapeutic market size in the 7MM was approximately USD 722 million in 2023.
In 2023, the Acute Pancreatitis market size was highest in the US among the 7MM, accounting for approximately USD 510 million which is further expected to increase by 2034 at a CAGR of 6.9%.
Leading Acute Pancreatitis companies working in the market are Boston Scientific Corporation, AnGes, Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Hemostemix Inc., Caladrius Biosciences, Reven Pharmaceuticals, New Beta Innovation Limited, BioGenCell Ltd., Abbott, and many others.
Key Acute Pancreatitis Therapies expected to launch in the market are CM-4620-IE, Evinacumab, SCM-AGH, and many others.
The estimates suggest that the gender based incidence varied in the 7MM with the male incident cases higher in the United Kingdom, Japan, and Germany, whereas in the United States the female incident cases were higher.
In approximately 15% of cases, patient can develop severe pancreatitis with tissue damage (also called Acute Necrotizing Pancreatitis (ANP)).
As per a study by Vege et al., the reported annual incidence of acute pancreatitis in the United States ranges from 4.9 to 35 per 100,000 population.
According to a study published by Ouyang et al., 2017, the incidence of acute pancreatitis ranges from 13 to 45 per 100,000 population-years and that of chronic pancreatitis ranges from 5 to 12 per 100,000 population-years.
Auxora is currently being evaluated in a Phase IIb trial for Acute Pancreatitis with accompanying SIRS, results of which are expected in first half of 2023; and in Phase I/II trial for Acute Pancreatitis in pediatric patients on asparaginase for acute lymphoblastic leukemia, results of which are expected in second half of 2022
CalciMedica: On November 13, 2024, CalciMedica announced positive data from the Phase 2b CARPO trial of Auxora (CRAC channel inhibitor) in patients with acute pancreatitis (AP). The trial showed a significant reduction in new-onset severe respiratory failure and persistent respiratory failure1. The company plans to initiate a Phase 3 program in 2025.
LipimetiX Development Inc: LipimetiX Development Inc is actively working on LipimetiX, a potential treatment for acute pancreatitis, with updates reported as of April 2024.
AcelRx Pharmaceuticals Inc: AcelRx Pharmaceuticals is developing AB-206, a drug for acute pancreatitis, with clinical trials ongoing as of April 2024.
Angion Biomedica Corp: Angion Biomedica Corp is working on Angion, a potential treatment for acute pancreatitis, with clinical trials ongoing as of April 2024.
Acute Pancreatitis Overview
Acute pancreatitis is a sudden inflammation of the pancreas, a gland located behind the stomach that plays a crucial role in digestion and blood sugar regulation. The condition can range from mild discomfort to a severe, life-threatening illness. It occurs when digestive enzymes become activated while still in the pancreas, causing the gland to begin digesting itself.
Common causes of acute pancreatitis include gallstones, which can block the pancreatic duct, and excessive alcohol consumption. Other causes may include certain medications, high triglyceride levels, abdominal trauma, infections, and genetic factors.
Symptoms typically include severe abdominal pain that radiates to the back, nausea, vomiting, fever, rapid pulse, and abdominal tenderness. Diagnosis is based on clinical presentation, blood tests showing elevated pancreatic enzymes (amylase and lipase), and imaging studies such as ultrasound, CT scans, or MRIs to assess inflammation and complications.
Treatment for acute pancreatitis usually requires hospitalization. Initial management focuses on fasting to rest the pancreas, intravenous fluids to maintain hydration, pain control, and treating the underlying cause. In severe cases, complications such as infections, cysts, or organ failure may necessitate more intensive treatments, including surgery or endoscopic procedures.
Most individuals recover fully with appropriate treatment, but severe cases can lead to chronic pancreatitis or other serious health issues, underscoring the importance of early diagnosis and intervention.
Do you know what will be the Acute Pancreatitis market share in 7MM by 2034 @ https://www.delveinsight.com/sample-request/acute-pancreatitis-market
Acute Pancreatitis Market
The Acute Pancreatitis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Acute Pancreatitis market trends by analyzing the impact of current Acute Pancreatitis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Acute Pancreatitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Acute Pancreatitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Acute Pancreatitis market in 7MM is expected to witness a major change in the study period 2020-2034.
Acute Pancreatitis Epidemiology
The Acute Pancreatitis epidemiology section provides insights into the historical and current Acute Pancreatitis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acute Pancreatitis market report also provides the diagnosed patient pool, trends, and assumptions.
Interested to know how the emerging diagnostic approaches will be contributing in increased Acute Pancreatitis diagnosed prevalence pool? Download report @ Acute Pancreatitis Market Dynamics
Acute Pancreatitis Drugs Uptake
This section focuses on the uptake rate of the potential Acute Pancreatitis drugs recently launched in the Acute Pancreatitis market or expected to be launched in 2020-2034. The analysis covers the Acute Pancreatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Acute Pancreatitis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acute Pancreatitis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Acute Pancreatitis Pipeline Development Activities
The Acute Pancreatitis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acute Pancreatitis key players involved in developing targeted therapeutics.
Download report to know which TOP 3 therapies will be capturing the largest Acute Pancreatitis market share by 2034? Click here @ Acute Pancreatitis Clinical Trials and Updates
Acute Pancreatitis Therapeutics Assessment
Major key companies are working proactively in the Acute Pancreatitis Therapeutics market to develop novel therapies which will drive the Acute Pancreatitis treatment markets in the upcoming years are Boston Scientific Corporation, AnGes, Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Hemostemix Inc., Caladrius Biosciences, Reven Pharmaceuticals, New Beta Innovation Limited, BioGenCell Ltd., Abbott, and many others.
Do you know how new drug market launch will be impacting the Acute Pancreatitis market CAGR? Download sample report @ Acute Pancreatitis therapies and drugs
Acute Pancreatitis Report Key Insights
1. Acute Pancreatitis Patient Population
2. Acute Pancreatitis Market Size and Trends
3. Key Cross Competition in the Acute Pancreatitis Market
4. Acute Pancreatitis Market Dynamics (Key Drivers and Barriers)
5. Acute Pancreatitis Market Opportunities
6. Acute Pancreatitis Therapeutic Approaches
7. Acute Pancreatitis Pipeline Analysis
8. Acute Pancreatitis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Acute Pancreatitis Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Acute Pancreatitis Competitive Intelligence Analysis
4. Acute Pancreatitis Market Overview at a Glance
5. Acute Pancreatitis Disease Background and Overview
6. Acute Pancreatitis Patient Journey
7. Acute Pancreatitis Epidemiology and Patient Population
8. Acute Pancreatitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Pancreatitis Unmet Needs
10. Key Endpoints of Acute Pancreatitis Treatment
11. Acute Pancreatitis Marketed Products
12. Acute Pancreatitis Emerging Therapies
13. Acute Pancreatitis Seven Major Market Analysis
14. Attribute Analysis
15. Acute Pancreatitis Market Outlook (7 major markets)
16. Acute Pancreatitis Access and Reimbursement Overview
17. KOL Views on the Acute Pancreatitis Market
18. Acute Pancreatitis Market Drivers
19. Acute Pancreatitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Canada News.Net
35 minutes ago
- Canada News.Net
Nasdaq Composite continues sliding, loses 73 points Thursday
NEW YORK, New York - Profit-taking continued to weigh on U.S. stock markets on Thursday with the technology sector again taking the most heat. "It's not a surprise to see some investors taking profits in tech stocks, which have had an incredibly strong run, with some up over 80 percent since the early April lows," Carol Schleif, chief market strategist at BMO Private Wealth told CNBC Thursday. "Market volume in general is typically quite sparse in late August leading to wider swings than fundamentals would warrant," she said. The broad S&P 500 (^GSPC) led the decline, falling 25.61 points to close at 6,370.17, a decrease of 0.40 percent. The sell-off was widespread, affecting various sectors and signaling a cautious mood among investors. The blue-chip Dow Jones Industrial Average (^DJI) also finished in the red, dropping 152.81 points to settle at 44,785.50, a loss of 0.34 percent. The tech-heavy NASDAQ Composite (^IXIC) mirrored the decline, shedding 72.54 points to end the day at 21,100.31, also down 0.34 percent. The simultaneous decline across all three major U.S. indexes suggests a broad-based pullback, potentially driven by profit-taking after a strong run and positioning ahead of upcoming economic reports that could influence the Federal Reserve's policy outlook. Analysts suggest that market participants are in a holding pattern, carefully weighing resilient economic data against the path of interest rates. All eyes are now turned to Friday's key jobs report for further direction on the health of the economy. U.S. Dollar Strengthens Against Major Rivals on Thursday The U.S. dollar flexed its muscles in foreign exchange markets on Thursday, posting broad gains against a basket of major currencies as market sentiment continued to favor the greenback. The dollar's strength was most pronounced against the Japanese yen. The USD/JPY pair surged to 148.39, a significant gain of 0.73 percent. This move underscores the widening policy divergence between the hawkish U.S. Federal Reserve and the Bank of Japan, which maintains its ultra-loose monetary stance despite commentary to the contrary. The euro and British pound both softened against the resilient dollar. The EUR/USD pair was a notable decliner, falling 0.40 percent to trade at 1.1604. Similarly, the GBP/USD pair dropped 0.31 percent to 1.3414 as the markets continued to assess the UK's economic outlook. The dollar also advanced against its Canadian counterpart. The USD/CAD pair rose 0.24 percent to reach 1.3905, attributed to the dollar's broader strength. In a significant move, the U.S. dollar rallied sharply against the Swiss franc, a traditional safe-haven currency. The USD/CHF pair climbed 0.65 percent to 0.8090, signaling a strong risk-on appetite among investors who favored the yield-bearing dollar. The commodity-linked Australian and New Zealand dollars continued to lose ground against the greenback, after Wednesday's sharp falls, particularly by the kiwi. The AUD/USD pair fell 0.20 percent to 0.6420, while the NZD/USD pair saw a more modest decline of 0.11 percent to 0.5816. The dollar's broad-based rally is largely fueled by expectations that the U.S. Federal Reserve will keep interest rates higher for longer to combat inflation, making dollar-denominated assets more attractive to investors seeking yield. This dynamic has created a strong bullish trend for the currency, pressuring its major peers across the board. Global Markets Deliver Mixed Bag; Asia-Pacific Shares Mostly Higher World markets presented a fractured performance in Thursday's trading, with strength in the Canadian, Asian and Pacific regions contrasting with a more subdued and mixed session across UK, European and other global bourses. Canada's S&P/TSX Composite Index (^GSPTSE) delivered a standout performance, climbing 176.67 points to finish at 28,055.43, a solid gain of 0.63 percent. The rally was likely fueled by strength in the energy and materials sectors The UK's FTSE 100 (^FTSE) edged up 21.06 points to 9,309.20, a gain of 0.23 percent. In Germany the DAX (^GDAXI) saw a minimal increase, adding 16.37 points (0.07 percent) to close at 24,293.34. However, France's CAC 40 (^FCHI) fell 34.74 points to 7,938.29, a decline of 0.44 percent. The pan-European EURO STOXX 50 (^STOXX50E) dipped 0.19 percent. Belgium's BEL 20 (^BFX) was a positive standout in the region, climbing 16.59 points to 4,835.48, up 0.34 percent. The Asia-Pacific region was a pocket of strength. Australia's S&P/ASX 200 (^AXJO) jumped 101.10 points, or 1.13 percent, to 9,019.10. The broader All Ordinaries index (^AORD) gained 106.80 points (1.16 percent) to 9,284.20. In New Zealand the S&P/NZX 50 (^NZ50) also posted a strong gain, rising 122.77 points to 13,194.07, up 0.94 percent. South Korea's KOSPI (^KS11) advanced 11.65 points (0.37 percent), while in Taiwan the TWSE Index (^TWII) was a top performer, surging 336.69 points, or 1.43 percent, to 23,962.13. Other Asian markets were more muted Thursday. Hong Kong's Hang Seng Index (^HSI) slipped 61.33 points (-0.24 percent). In Japan the Nikkei 225 (^N225) retreated from recent highs, falling 278.38 points to 42,610.17, a loss of 0.65 percent. Indonesia's IDX Composite (^JKSE) declined 53.11 points (-0.67 percent), while Malaysia's FTSE Malaysia KLCI (^KLSE) gained a modest 4.66 points (0.29 percent). In India, the BSE Sensex (^BSESN) eked out a gain of 142.87 points (0.17 percent) to close above the 82,000 mark. In the EMEA region, Israel's TA-125 (^ advanced 20.93 points (0.69 percent). In Egypt the EGX 30 (^CASE30) went against the trend, falling 109.50 points to 35,622.30, down 0.31 percent.
Cision Canada
5 hours ago
- Cision Canada
MARBLEX'S NEW TOY-INSPIRED PIXEL RPG META TOY DRAGONZ SAGA SURPASSES 500,000 GLOBAL PRE-REGISTRATIONS
SEOUL, South Korea, Aug. 21, 2025 /CNW/ -- Blockchain gaming company MARBLEX announced that its upcoming pixel art collectible RPG Meta Toy Dragonz Saga has surpassed 500,000 global pre-registrations, signaling strong anticipation ahead of its official launch later this month. Developed by Sandbox Network and published through MARBLEX's innovative Web3 Publishing Model, Meta Toy Dragonz Saga combines nostalgic pixel art with modern blockchain elements, offering players over 300 unique "Toy Dragons" to collect, train, and battle. Pre-registration is now open on both the Google Play Store and Apple App Store, with global launch scheduled for the end of August. Earlier this year, MARBLEX unveiled its 2025 Roadmap under the slogan FUN COMES FIRST. As part of this initiative, the company introduced its Web3 Model—an evolved approach that goes beyond simple game onboarding. This model emphasizes in-depth evaluation, close collaboration with developers, customized blockchain and business model design, one-stop integration, and robust marketing support. Backed by a joint fund of over USD 20 million with Immutable, MARBLEX reinvests revenue share fees into its ecosystem to drive token value, foster community growth, and accelerate the expansion of its Web3 gaming lineup. Building on the momentum of Self-made Billionaire: Stock Game and Meta Toy Dragonz Saga, MARBLEX is preparing to onboard additional titles in the second half of 2025, including Dice Go! (Real-time Monopoly PvP) and Kritika (ARPG). More information can be found on the MARBLEX's official website, Medium, Telegram, and X. MARBLEX is a blockchain-powered subsidiary of Netmarble Corp. Netmarble Corp. is a well-established developer and publisher of mobile games composed of more than 6,000 game industry veterans and blockchain technology experts from across the globe. MARBLEX aims to bring the highest quality blockchain games to market by providing key services such as a cryptocurrency wallet, decentralized exchange, token staking, and an NFT Marketplace. MBX, a proprietary blockchain ecosystem launched by MARBLEX, allows gamers to advance their experiences through organic engagement and rewards for participation. The MBX ecosystem can be enjoyed as part of popular Netmarble titles, such as Meta World: My City, A3: Still Alive and Ni no Kuni: Cross Worlds.
Cision Canada
7 hours ago
- Cision Canada
US Drone Land Surveying Market Projected to Reach $14 Billion By 2030 as Government Uses Increase
NEW YORK, /CNW/ -- The land surveying market is being revitalized by the emergence of drone technology, offering a more efficient, accurate, safer, and cost-effective approach to data collection and analysis. Industry insiders are saying that in recent years, drone land surveying has become a groundbreaking solution for professionals in land assessment, mapping, and surveying industries. By leveraging UAV technology, land surveyors can now complete projects faster, more efficiently, and with a level of precision previously unattainable using traditional methods. Unlike conventional techniques, drones provide quick data collection with minimal human intervention, enhancing productivity while reducing costs. This new wave of innovation is transforming industries such as construction, agriculture, and environmental management. The integration of UAV technology allows surveyors to gather aerial imagery in real-time, generating highly detailed and accurate maps for topographic mapping and other vital surveying applications. As this technology evolves, the demand for more sophisticated data analysis and quicker survey turnaround times continues to rise. By embracing drones, land surveyors can now offer services that were previously time-consuming and expensive. With drones in the field, traditional surveying methods are quickly becoming a thing of the past, making way for the future of land surveying." Active Companies in the Drone Industry today include ZenaTech, Inc. (NASDAQ: ZENA), Draganfly Inc. (NASDAQ: DPRO), AgEagle Aerial Systems Inc. (NYSE: UAVS), Lantronix Inc. (NASDAQ: LTRX), Red Cat Holdings Inc. (NASDAQ: RCAT). GOOGLE AI searches say that the global drone surveying and mapping service market was valued at USD 1.42 billion in 2024 and is projected to reach USD 6.7 billion by 2035, growing at a CAGR of 17.1%; and the US drone land surveying market alone is projected to grow significantly, reaching an estimated value of USD 14.55 billion by 2030. According to "The core of UAV drone land surveying is the combination of sophisticated aerial systems and powerful software that work together to collect, process, and analyze data. Surveying drones equip high-definition cameras, LiDAR sensors, and other advanced technologies, enabling precise geospatial analysis. These aerial systems capture aerial imagery from multiple angles, enabling the creation of detailed 2D and 3D models of the surveyed area. The software used alongside drones plays a critical role in the processing and analysis of collected data. Surveying software enables professionals to stitch images together, process LiDAR point clouds, and generate accurate topographic maps. The integration of UAV technology with mapping software ensures that the collected data is processed quickly, accurately, and in real-time." ZenaTech (NASDAQ:ZENA) Signs Agreements to Acquire Two Florida Companies, Expanding Drone as a Service Footprint into Aviation, Defense, and Power Washing - ZenaTech, Inc. (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, announces it has signed offers to acquire two Florida-based companies expected to expand its US DaaS services footprint into drone-based power washing and new aviation, defense, government, and commercial customers. The acquisitions will unlock significant revenue potential as well as diversification across the Southeast region and nationally. One proposed acquisition is a Florida-based power wash services company with operations across multiple counties, marking ZenaTech's first US entry into the power washing sector. This acquisition will provide ZenaTech with a platform to scale drone-enabled power wash services rapidly to new markets, including airplane maintenance, aviation facilities, and defense infrastructure. Power washing in aviation uses high-pressure water and drone-assisted cleaning systems to remove dirt, debris, and contaminants from aircraft exteriors and infrastructure, and cleans and sanitizes interiors. The sector is poised to grow due to increasing fleet sizes, stricter safety and efficiency standards, and the rising adoption of automated, eco-friendly maintenance technologies. An additional proposed acquisition is a land surveying firm with over 30 years of history serving Florida-based developers and homebuilders. With a long-standing client base and trusted reputation, the Company believes this partnership will enhance its Southeast region DaaS presence and create a strong platform to expand drone services across additional construction and real estate customers, further consolidating the company's regional footprint. "When finalized, these acquisitions will provide diversification and future revenue streams for Drone as a Service across our Southeast and national networks," said Shaun Passley, Ph.D., ZenaTech CEO. "Expanding our reach to aviation and defense is strategic as we believe the future of aviation maintenance is autonomous. By replacing ladders, scaffolding, and chemical-heavy processes with smart cleaning drones, for both interior and exteriors of planes, we hope to help airlines and defense operators set a new standard for safety, sustainability, and efficiency." ZenaTech has closed eight US acquisitions toward its goal of establishing 25 Drone as a Service locations across the US by mid-2026. The company's DaaS model is designed to provide flexible, on-demand access to drone services for surveying, inspections, maintenance, power washing, precision agriculture and more, eliminating the need to have to invest in drone hardware and software, worry about maintenance, regulatory compliance, or finding pilots. The company's strategy is aimed at acquiring established land survey engineering firms, and other old-tech or manual service businesses that are ripe for drone innovation, to advance its national vision for a scalable, tech-enabled multiservice drone business anchored by existing customers, recurring revenue, and new growth opportunities. Continued… Other developments in the drone/UAV industries include: Draganfly Inc. (NASDAQ: DPRO) an award-winning, industry-leading drone solutions and systems developer, recently announced its second quarter financial results. Key Financial and Operational Highlights for Q2 2025 were: Revenue for the second quarter of 2025 was $2,115,255 which represents a 22.1% year over year increase. Product sales of $1,901,585 were up 37.1% over the same period last year. Gross profit for Q2 2025 was $504,592 up 9.3% from $461,673 for the same period last year. Gross margin percentage for Q2 2025 was 23.9% compared to 26.6% in Q2 2024. Gross profit would have been $515,013 and gross margin would have been 24.3%, not including a one-time non-cash recovery of a write down of inventory of $10,421. The decrease is due to the sales mix of the products sold. The comprehensive loss for the period of $4,749,634 includes non-cash changes comprised of a negative change in fair value derivative of $180,318, a write down of inventory of $10,421, and an impairment gain on notes receivable of $8,233 and would otherwise be a comprehensive loss of $4,567,128 vs an adjusted comprehensive loss of $4,362,944 for the same period last year. Contributors to the year-over-year increase are increased office and miscellaneous, employee and management expenses, and share based payments, offset by professional fees. Cash balance on June 30, 2025 of $22,571,059 compared to $6,252,409 on December 31, 2024. AgEagle Aerial Systems Inc. (NYSE: UAVS), a leading provider of advanced drone and aerial imaging solutions, recently announced their partner in Colombia, Drummond Ltd., a leader in mining sector innovation, was granted multiple certifications for advanced drone operations in-country by the Civil Aeronautics Authority (CAA) in Colombia. The CAA authorizations cover BVLOS (Beyond Visual Line of Sight), night flights, and multi-drone operations (One-to-Many) for Drummond, using the eBee X drone. "We are very proud of Drummond's new levels of certification which result in greater operational capabilities," said Bill Irby, CEO of AgEagle. "Their commitment to expanding what is possible with unmanned systems using the eBee X drone represent a significant step forward in the control, safety, and oversight of Colombian airspace, as well as enhanced safety and efficiencies in their mining operations." Lantronix Inc. (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions powering Edge AI applications, recently announced that its TAA- and NDAA-compliant solution was selected by Teal Drones, a Red Cat Holdings Inc. (NASDAQ: RCAT) company, for production of its Black Widow™ drones under the U.S. Army's Short-Range Reconnaissance (SRR) Program. Lantronix has already initiated production shipments, providing early revenue visibility and underscoring Lantronix's role as a trusted technology partner for mission‑critical defense applications. The Lantronix solution, based on the Qualcomm® Dragonwing™ QRB5165 processor, delivers advanced Edge AI processing while meeting stringent U.S. security requirements, enabling full TAA and NDAA compliance for deployment in sensitive Department of Defense (DoD) missions. The combination of AI performance and compliance creates a sustainable advantage for Lantronix in the rapidly expanding defense and autonomous systems market. As part of a select group of Blue UAS-approved small Unmanned Aerial Systems (sUAS) vendors, Teal Drones must meet rigorous cybersecurity, operational and safety standards for DoD use. Lantronix's compliant solution enables Teal to meet these requirements, positioning its Black Widow drones for deployment in frontline missions. DISCLAIMER: (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated fifty one hundred dollars for news coverage of the current press releases issued by ZenaTech, Inc. by the Company. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
